Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 774

Results For "GE"

7982 News Found

Evexia Lifecare to manufacture API of Isometa
News | August 03, 2021

Evexia Lifecare to manufacture API of Isometa

Robust demand for the product across the Middle East, Africa and Latin America


Nureca Ltd PAT at Rs 36.19 crore in Q1FY22
Healthcare | August 03, 2021

Nureca Ltd PAT at Rs 36.19 crore in Q1FY22

Nureca Ltd has reported financial results for the period ended June 30, 2021.


Morepen Laboratories posts Q1FY22 consolidated PAT of Rs. 30.47 Cr
News | August 03, 2021

Morepen Laboratories posts Q1FY22 consolidated PAT of Rs. 30.47 Cr

The company posted net profit of Rs.19.36 crores for the period ended June 30, 2020.


Abbott's Freestyle Libre 2 Ios App Cleared In U.S
Drug Approval | August 03, 2021

Abbott's Freestyle Libre 2 Ios App Cleared In U.S

FreeStyle Libre 2 iOS app is the only sensor-based glucose monitoring app that allows users to check their glucose with a compatible iPhone every minute with optional real-time glucose alarms


API exports surpass imports by value in 2020-21
Policy | August 03, 2021

API exports surpass imports by value in 2020-21

The govt has rolled out three schemes for promoting the manufacture of API


Drug exports grow on the back of govt support
Policy | August 03, 2021

Drug exports grow on the back of govt support

Drug formulations and biologics make impressive gains


AYUSH 64 effective in mild and moderate COVID 19
Drug Approval | August 03, 2021

AYUSH 64 effective in mild and moderate COVID 19

It works as an adjunct to standard care based on robust clinical trials


Krsnaa Diagnostics public issue opens from Aug 4-6th 2021
Healthcare | August 02, 2021

Krsnaa Diagnostics public issue opens from Aug 4-6th 2021

Price band in the range of Rs 933 to Rs 954


Glenmark signs agreement with SaNOtize to manufacture NONS
News | August 02, 2021

Glenmark signs agreement with SaNOtize to manufacture NONS

The Phase III clinical trial for NONS is expected to be completed by Q4 2021.


Ajanta Pharma aims to file 10-12 ANDAs per annum
News | August 02, 2021

Ajanta Pharma aims to file 10-12 ANDAs per annum

India business is growing as per projections; whereas US business will bounce back soon.